News

Garry A. Neil to Lead Presentations at Notable Investor Events

Garry A. Neil to Lead Presentations at Notable Investor Events

Garry A. Neil to Speak at Upcoming Investor Conferences

Avalo Therapeutics, Inc. (NASDAQ: AVTX) is making headlines with its participation in significant investor conferences slated for the coming months. The spotlight will be on Garry A. Neil, M.D., the Chief Executive Officer and Chairman of the Board, who is set to share insights and significant developments regarding the company’s innovative approaches to treating immune dysregulation.

Details of the Conferences

The first event is the highly anticipated Stifel 2024 Healthcare Conference, where Dr. Neil will present on Monday, November 18, 2024, at 3:35 PM ET. Following that, he will also take part in the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 5, 2024, at 11:00 AM ET.

Accessing the Presentations

For those unable to attend these conferences in person, Avalo Therapeutics will offer live webcasts featuring Dr. Neil’s presentations. Interested parties can find the webcasts and replays in the Investors section under "News / Events" on the Avalo Therapeutics website. These archived sessions will be accessible for a minimum of 30 days, ensuring that stakeholders can stay informed about Avalo's progress and insights.

About Avalo Therapeutics and Its Mission

Avalo Therapeutics, founded with a primary focus on clinical stage biotechnology, is dedicated to advancing treatments for immune dysregulation. At the forefront of Avalo's research is its lead asset, AVTX-009, a groundbreaking anti-IL-1? monoclonal antibody designed to combat inflammatory diseases.

Innovative Therapeutics

Avalo Therapeutics' product lineup includes innovative drug candidates such as quisovalimab (an anti-LIGHT mAb) and AVTX-008 (a BTLA agonist fusion protein). These candidates aim to provide targeted solutions for patients suffering from various autoimmune and inflammatory conditions.

Understanding AVTX-009

AVTX-009 stands out as a humanized monoclonal antibody with specific affinity for interleukin-1? (IL-1?), a pivotal molecule in the inflammation cascade. Elevated or poorly regulated levels of IL-1? are linked to numerous autoimmune and inflammatory diseases. By inhibiting IL-1? activity, AVTX-009 may offer therapeutic benefits for conditions such as hidradenitis suppurativa, among others in the fields of dermatology, gastroenterology, and rheumatology.

Inquiries for Investors and Media

For any inquiries regarding investor relations or media questions, Christopher Sullivan, CFO of Avalo Therapeutics, is available for contact. Interested individuals can reach out via email or phone, with his contact details provided: ir@avalotx.com and 410-803-6793.

Additionally, inquiries can also be directed to Meru Advisors, represented by Lauren Glaser, at lglaser@meruadvisors.com.

Frequently Asked Questions

What is Avalo Therapeutics known for?

Avalo Therapeutics is a clinical stage biotechnology company focusing on treatments for immune dysregulation, particularly through its innovative drug candidates.

Who will present at the investor conferences?

Dr. Garry A. Neil, the CEO and Chairman of Avalo Therapeutics, will lead the presentations at the upcoming healthcare conferences.

When are the upcoming conferences?

The Stifel 2024 Healthcare Conference is scheduled for November 18, 2024, and the Piper Sandler 36th Annual Healthcare Conference will take place on December 5, 2024.

How can I access the conference presentations?

The live webcasts and replays of the presentations will be available on the Avalo Therapeutics website under the Investors section.

What is AVTX-009?

AVTX-009 is a humanized monoclonal antibody that targets interleukin-1?, which plays a significant role in the inflammatory process related to various autoimmune and inflammatory diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Morgan Conque: Veterans' Assets Meet Business Leadership

Updated Category News Views 73

Celebrating Veterans in Business When the world's largest tribute to veteran talent lands in Dallas on December 10, it won't just be about pomp and ceremony. It's about showcasing remarkable stories like Morgan Conque's—someone who's managed to transcend her past military distinction and drive the business world with the same vigor. From Military Precision to Business...

Continue Reading
Whimstay's Gambit: Holiday Rentals Savings Game

Updated Category News Views 114

The Bargain Hunt: Last-Minute Savings Whimstay is dangling a carrot for those looking to snag a holiday rental without burning through wads of cash. With the 2026 holiday season barreling down like a freight train, travelers are scouring for deals that won’t sink their budgets. Whimstay's shtick? Enticing discounts for folks who can wrestle with last-minute booking...

Continue Reading
SM Investments Wins Five Golden Arrows: Governance on Point

Updated Category News Views 118

Gold Arrows and Golden Standards What’s in a bunch of gold arrows, you might ask? Well, for SM Investments Corporation, those Five Golden Arrows from the Institute of Corporate Directors aren't just shiny trinkets. They're badges of honor, symbols of a rock-solid governance fortress. For the third year running, they’ve nailed the top spot under the corporate...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 54

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading
Pen Needles Market to Hit $3.37B by 2031: Growth Ahead

Updated Category News Views 110

Big Numbers in the Needle Game When you're staring down the numbers popping out of this pen needles market projection, it's hard to ignore—shooting from a respectable $2.16 billion in 2026 to a hefty $3.37 billion by 2031. We're talking a 9.3% CAGR that'll have investors pulling out their calculators or maybe rubbing their hands in downright glee, depending on their...

Continue Reading
Sun Home Goes Big with Black Friday Sauna Extravaganza

Updated Category News Views 62

Sun Home's Black Friday Warm-Up If ever there was a time to crank up the heat on a deal, it’s right now. Sun Home Saunas, a San Diego stalwart in the home wellness space, launched their Black Friday blitz today, offering savings that's hotter than a summer day in Death Valley. Between November 6 and December 7, they're slashing prices left and right, tossing in free...

Continue Reading
Tetragon Declares Dividend Amidst Regulation Challenges

Updated Category News Views 112

What Keeps Investors on Their Toes Tetragon Financial Group is ringing the dividend bell again—a solid 12 cents a share coming your way. But don't just kick your feet up and watch the cash roll in; there's a tangle of juicy tidbits and regulatory strings attached that make this more than your run-of-the-mill payout announcement. A Look at the Dividend Breakdown For...

Continue Reading
Elanco Surges with Solid Q3, Raises 2026 Forecast

Updated Category News Views 71

Strong Q3 Performance Ignites Elanco's Growth Now here's a headline: Elanco's numbers are charging like a bull on steroids. Revenue surged 11% year-over-year to hit a cool $1.265 billion, showing off a 9% organic constant currency growth. And why should we, the investors, care? Because they've adjusted their EBITDA margin upwards to 19.5%, an impressive 2% boost from the...

Continue Reading
Andersen's Window Revamp: Addressing Demand Surge

Updated Category News Views 75

Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...

Continue Reading
TELUS Targets Debt Reduction Amid Telecom Transformation

Updated Category News Views 86

Adjusting Strategy Amid Financial Challenges The market's a tough beast, and TELUS seems to be wrestling with it, showing both grit and foresight in its latest quarterly update. Third quarter 2026 has TELUS down on revenues with a notable net loss but don't count them out yet. Their Transformation Strategy is a gamble worth watching. Where the Numbers Stand Here's the...

Continue Reading

Top 5 Most Recently Viewed Articles

Frontera Energy Corporation Joins OTCQX for Enhanced Trading

Updated Category News Views 160

Frontera Energy Corporation Joins OTCQX for Enhanced Visibility Frontera Energy Corporation, a Canadian company specializing in the exploration and production of oil and natural gas in South America, has officially transitioned to the OTCQX® Best Market. This upgrade from the OTCID™ Basic Market signifies not only a pivotal milestone for the company but also a...

Continue Reading
Exciting New Consumer Product Launches You Must Know Now

Updated Category News Views 745

Exciting New Consumer Product Launches In an ever-evolving consumer market, keeping up with the latest product launches can be thrilling yet overwhelming. Recently, several brands unveiled innovative products that have captivated audiences and are making waves in various retail sectors. Here's a roundup of some of the most notable announcements that consumers and industry...

Continue Reading
Workhorse Stock Surge: A Promising Future for WKHS

Updated Category News Views 375

Overview of Workhorse Group, Inc. Workhorse Group, Inc. (NASDAQ: WKHS), a notable player in the electric vehicle (EV) sector, specializes in developing innovative technologies for last-mile delivery, blending electric vehicles and drone tech. The stock has experienced notable fluctuations, trading close to three times its 50-day moving average recently, reflecting the...

Continue Reading
Capricor Therapeutics Investors May Join Class Action Lawsuit

Updated Category News Views 145

Capricor Therapeutics Faces Legal Challenges Capricor Therapeutics, Inc. (NASDAQ: CAPR) finds itself in troubled waters as several shareholders have lost significant money on their investments. This situation has prompted investors to consider a class action lawsuit against the company. Accusations relate to misleading information presented about their promising drug...

Continue Reading
General Mills Faces Challenges Amid Downgraded Outlook and Pricing Struggles

Updated Category News Views 207

Wall Street's Gloomy Outlook on General Mills From where I sit, it’s getting a bit murky for General Mills Inc. (NYSE:GIS). Analysts are starting to sing a different tune, and not the kind that’ll get investors dancing. This takes me back to those tough times after the dot-com bust. Recently, BofA Securities analyst Peter T. Galbo pulled the rug out from under GIS,...

Continue Reading